-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Drug production is a major event related to people's livelihood and directly affects the health and safety of the peop.
At present, under the major changes in the pharmaceutical industry, some pharmaceutical companies are facing difficulties such as falling prices, rising raw material costs, and insufficient research and development motivation, and their operations are affected to a certain exte.
In order to help pharmaceutical companies expand capacity and increase efficiency, in recent years, relevant departments in many places have begun to accelerate the development of pharmaceutical companies through tax rebates and tax reductio.
It is reported that some pharmaceutical companies have faced certain difficulties in their operation in recent yea.
They have invested a lot in various equipment, and the pressure on capital turnover is hi.
Coupled with the impact of the epidemic, they have been moving forward under heavy burde.
Therefore, after understanding the specific situation of the company, the State Administration of Taxation Hangzhou The city's Linping District Taxation Bureau has helped the enterprise cadres to tailor a "package" of tax and fee concessions for the pharmaceutical enterprise, and guided the enterprise to submit relevant applications and enjoy various tax and fee bonus.
With only one tax rebate left, the company enjoyed a discount of 27934 million yu.
In addition, a pharmaceutical company in Hubei has taken advantage of the "spring breeze" of tax reduction and fee reduction in recent years, and has also enjoyed the capital dividend brought by a series of preferential tax policies such as export tax rebates and additional deductions for R&D expenses through the tax departme.
This has brought positive incentives to enterprises, which not only encouraged enterprises to increase investment in technology research and development to stimulate innovation momentum, but also helped enterprises cultivate a group of talents with outstanding core technical capabiliti.
Among them, it is worth mentioning that the company also uses the funds saved by tax reduction and fee reduction for the recruitment of corporate R&D personnel and the development and research of new technologi.
At present, its key leading products such as progesterone have been registered in India and the European Uni.
On the whole, China's pharmaceutical industry has developed rapidly in recent years under the influence of a series of new medical reform policies such as the consistency evaluation of generic drugs and the encouragement of new drug research and developme.
But at the same time, competition between industries is also intensifyi.
Affected by this, cost reduction, efficiency enhancement and quality improvement are gradually becoming important challenges for pharmaceutical compani.
In order to meet these challenges and better help pharmaceutical companies to expand capacity and increase efficiency, policy assistance is not enough; industry analysts believe that pharmaceutical companies still need to transform and upgrade in the direction of intelligent manufacturing to further expand production capacity, improve production efficiency and product quali.
By improving the automation and informatization level of pharmaceutical equipment, the bottleneck problem of traditional pharmaceutical machines can be effectively solved, and the stability and productivity of pharmaceutical production quality can be improved through automated contr.
At the same time, combined with online testing equipment, each production step can be obtained more timely and efficient.
The quality inspection data is analyzed and analyzed, so as to optimize the pharmaceutical process and production process, and reduce costs and energy consumpti.
At present, many large domestic pharmaceutical machine companies have accelerated the development of pharmaceutical intelligent manufacturi.
For example, some companies have already taken firm steps of exploration in product research and development and proactively meeting customer nee.
They are all actively exploring pharmaceutical intelligence and information technolo.
” There is also Chutian Technology, in order to help the development of pharmaceutical intelligent manufacturing, it also announced earlier that it plans to spend 51 million yuan to set up a holding subsidiary, which will provide bioengineeri.
The main business is the overall solution of downstream separation and purification and supporting processes, consumables, equipment and core components such as pumps and valv.
It is worth mentioning that the new intelligent manufacturing model project launched by Truking Technology in February 2016 has also passed the acceptan.
The implementation of this project will realize the whole product life cycle management from R&D, manufacturing, logistics, service, e.
, create a new intelligent manufacturing mode and intelligent manufacturing standard of pharmaceutical equipment, and further promote the transformation of China's pharmaceutical equipment enterprises to a new mode of intelligent manufacturi.
In general, with the rapid economic development and the increasingly fierce competition among enterprises, the demand of pharmaceutical companies for capacity expansion and efficiency will continue to gr.
In the future, whoever can further save costs for enterprises and expand production capacity on the premise of ensuring quality will be able to seize more marke.
In this context, for pharmaceutical machine companies, if they want to seize the development opportunities, they must follow the industry closely by strengthening the research and development of intelligent products and moving towards a path of mechanical automation, unmanned operation, higher added value and more innovati.
Trend, continue to meet the needs of pharmaceutical compani.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
At present, under the major changes in the pharmaceutical industry, some pharmaceutical companies are facing difficulties such as falling prices, rising raw material costs, and insufficient research and development motivation, and their operations are affected to a certain exte.
In order to help pharmaceutical companies expand capacity and increase efficiency, in recent years, relevant departments in many places have begun to accelerate the development of pharmaceutical companies through tax rebates and tax reductio.
It is reported that some pharmaceutical companies have faced certain difficulties in their operation in recent yea.
They have invested a lot in various equipment, and the pressure on capital turnover is hi.
Coupled with the impact of the epidemic, they have been moving forward under heavy burde.
Therefore, after understanding the specific situation of the company, the State Administration of Taxation Hangzhou The city's Linping District Taxation Bureau has helped the enterprise cadres to tailor a "package" of tax and fee concessions for the pharmaceutical enterprise, and guided the enterprise to submit relevant applications and enjoy various tax and fee bonus.
With only one tax rebate left, the company enjoyed a discount of 27934 million yu.
In addition, a pharmaceutical company in Hubei has taken advantage of the "spring breeze" of tax reduction and fee reduction in recent years, and has also enjoyed the capital dividend brought by a series of preferential tax policies such as export tax rebates and additional deductions for R&D expenses through the tax departme.
This has brought positive incentives to enterprises, which not only encouraged enterprises to increase investment in technology research and development to stimulate innovation momentum, but also helped enterprises cultivate a group of talents with outstanding core technical capabiliti.
Among them, it is worth mentioning that the company also uses the funds saved by tax reduction and fee reduction for the recruitment of corporate R&D personnel and the development and research of new technologi.
At present, its key leading products such as progesterone have been registered in India and the European Uni.
On the whole, China's pharmaceutical industry has developed rapidly in recent years under the influence of a series of new medical reform policies such as the consistency evaluation of generic drugs and the encouragement of new drug research and developme.
But at the same time, competition between industries is also intensifyi.
Affected by this, cost reduction, efficiency enhancement and quality improvement are gradually becoming important challenges for pharmaceutical compani.
In order to meet these challenges and better help pharmaceutical companies to expand capacity and increase efficiency, policy assistance is not enough; industry analysts believe that pharmaceutical companies still need to transform and upgrade in the direction of intelligent manufacturing to further expand production capacity, improve production efficiency and product quali.
By improving the automation and informatization level of pharmaceutical equipment, the bottleneck problem of traditional pharmaceutical machines can be effectively solved, and the stability and productivity of pharmaceutical production quality can be improved through automated contr.
At the same time, combined with online testing equipment, each production step can be obtained more timely and efficient.
The quality inspection data is analyzed and analyzed, so as to optimize the pharmaceutical process and production process, and reduce costs and energy consumpti.
At present, many large domestic pharmaceutical machine companies have accelerated the development of pharmaceutical intelligent manufacturi.
For example, some companies have already taken firm steps of exploration in product research and development and proactively meeting customer nee.
They are all actively exploring pharmaceutical intelligence and information technolo.
” There is also Chutian Technology, in order to help the development of pharmaceutical intelligent manufacturing, it also announced earlier that it plans to spend 51 million yuan to set up a holding subsidiary, which will provide bioengineeri.
The main business is the overall solution of downstream separation and purification and supporting processes, consumables, equipment and core components such as pumps and valv.
It is worth mentioning that the new intelligent manufacturing model project launched by Truking Technology in February 2016 has also passed the acceptan.
The implementation of this project will realize the whole product life cycle management from R&D, manufacturing, logistics, service, e.
, create a new intelligent manufacturing mode and intelligent manufacturing standard of pharmaceutical equipment, and further promote the transformation of China's pharmaceutical equipment enterprises to a new mode of intelligent manufacturi.
In general, with the rapid economic development and the increasingly fierce competition among enterprises, the demand of pharmaceutical companies for capacity expansion and efficiency will continue to gr.
In the future, whoever can further save costs for enterprises and expand production capacity on the premise of ensuring quality will be able to seize more marke.
In this context, for pharmaceutical machine companies, if they want to seize the development opportunities, they must follow the industry closely by strengthening the research and development of intelligent products and moving towards a path of mechanical automation, unmanned operation, higher added value and more innovati.
Trend, continue to meet the needs of pharmaceutical compani.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
